3rd Quarter - Report

TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$222,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 20, 2015 $222,000 Replaced
3rd Quarter - Amendment Jan 20, 2016 $260,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

H.R. 3204: The Drug Quality and Security Act

LobbyistCovered position, as disclosed
DEBORAH LYNN WALTER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3204 (114th)

Copyright/Patent/Trademark CPT

H.R. 9

LobbyistCovered position, as disclosed
SHELLEY STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 9 (114th)

Health Issues HCR

H.R. 6: 21st Century Cures

LobbyistCovered position, as disclosed
SHELLEY STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); Alzheimer's disease Part D coverage

LobbyistCovered position, as disclosed
SHELLEY STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2404 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.